Answers are grounded in this paper and cite their sources.
This article discusses the neologism ‘palliadelic’ to designate the use of psychedelics in palliative care (PC) settings. Combining the concepts of ‘palliative’ and ‘psychedelic’, the term aims to describe interventions that use psychedelic substances to alleviate the psychological, spiritual, and existential suffering of patients with serious or incurable illnesses, or at the end of life. Based on a historical and conceptual review, the text addresses the evolution of the use of psychedelics in medical and cultural settings, highlighting their applications in PC from the pioneering studies conducted in the 1950s and 1960s to the current psychedelic renaissance. In addition, it discusses the conceptual foundations of ‘palliative’ and ‘psychedelic’, emphasizing the importance of terminology for the consolidation of emerging fields in science. It is argued that the use of the neologism ‘palliative’ not only legitimates a growing body of knowledge, but also promotes advancements in research, clinical practice, and public policies directed toward compassionate and innovative care at the end of life. It is concluded that the adoption of ‘palliadelic’ as a core concept can increase the visibility and integration of the therapeutic use of psychedelics in PC, contributing to the humanization of care and the reduction of suffering in end-of-life settings.
No takes yet. Share an insight, caveat, or question.
Barco et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: